Lantheus to Present at March 2026 Investor Conferences
Rhea-AI Summary
Lantheus (NASDAQ: LNTH) announced that Mary Anne Heino, Executive Chairperson and CEO, will present at two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 11:10 a.m. ET and Leerink Global Healthcare Conference on March 10, 2026 at 8:00 a.m. ET.
Live webcasts will be accessible via the Investors section of the company's website, with replays available for at least 30 days following each presentation.
Positive
- None.
Negative
- None.
News Market Reaction – LNTH
In the Feb 24 session, LNTH gained 0.26%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Earnings call notice | Neutral | +2.1% | Scheduled Q4 and full-year 2025 earnings call and webcast announcement. |
| Jan 02 | Business divestiture | Positive | +1.1% | Completed sale of SPECT business to refocus on PET and radiopharmaceuticals. |
| Nov 24 | Clinical data presentation | Positive | +1.2% | Announced florbetaben F 18 data presentation at CTAD 2025 conference. |
| Nov 06 | Earnings & guidance | Mixed | -6.2% | Reported Q3 2025 results, updated guidance, and multiple PDUFA dates. |
| Nov 06 | Leadership transition | Mixed | -6.2% | Announced CEO retirement, interim leadership, and broader executive changes. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent LNTH news has often coincided with modest positive moves for routine updates, while the November 2025 earnings and leadership transition releases saw notably negative reactions.
Over the last few months, LNTH has reported several milestones: an upcoming Feb 26, 2026 earnings call, completion of the SPECT business sale on Jan 2, 2026, and new florbetaben F 18 data at CTAD 2025. Earlier, Q3 2025 results and a leadership transition on Nov 6, 2025 were followed by a -6.19% move, contrasting with the generally positive reactions (+1.08% to +2.14%) to conference and data announcements. Today’s conference-participation news fits this pattern of ongoing investor and scientific engagement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced Mary Anne Heino, Executive Chairperson and Chief Executive Officer, will present at the following investor conferences.
- TD Cowen 46th Annual Health Care Conference
March 3, 2026 at 11:10 a.m. ET - Leerink Global Healthcare Conference
March 10, 2026 at 8:00 a.m. ET
To access the live webcast of the presentations, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcasts will be available on the Company’s website for at least 30 days following the live presentation.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.
Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Executive Director, External Communications
646-975-2533
media@lantheus.com
